Horiba, Ltd. · TSE:6856

Horiba — Q1 2024 Earnings Presentation

15 slides from Horiba's earnings presentation, May 20, 2024

  1. Slide 1: Financial Information

    Financial Information HORIBA, Ltd. May, 2024 1 © 2024 HORIBA, Ltd. All rights reserved.

  2. Slide 2: Contents

    Contents ◼ 2024 1Q (Jan.- Mar.) Results ◼ 2024 Forecasts ◼ Operating Profit Analysis ◼ Exchange Rate Impact ◼ CAPEX, Depreciation, R&D Expenses ◼ Shareholder Return ◼ Topics in 3 Fields © 2024 HORIBA, Ltd. All rights reserved. 2

  3. Slide 3: 2024 1Q (Jan.-Mar.) Results

    2024 1Q (Jan.-Mar.) Results (Billions of yen) Sales was record-high, but net income attributable to HORIBA, Ltd.’s shareholders decreased due to the gain on the sale of shares of subsidiaries in previous year 2023 2024 vs 2023 1Q Results 1Q Results Changes % (Jan.-Mar.) (Jan.-Mar.) Sales 65.8 70.2 +

  4. Slide 4: 2024 1Q (Jan.-Mar.) Results by Segment

    2024 1Q (Jan.-Mar.) Results by Segment (Billions of yen) Sales Operating profit 2023 2024 vs 2023 2023 2024 vs 2023 1Q Results 1Q Results 1Q Results 1Q Results Changes % Changes % (Jan.-Mar.) (Jan.-Mar.) (Jan.-Mar.) (Jan.-Mar.) Auto 15.9 19.5 +3.5 +22.5% 0.3 0.1 -0.1 -46.0% P&E 5.4 5.9 +0.5 +9.9% 0.

  5. Slide 5: 2024 Forecasts

    2024 Forecasts (Billions of yen) Forecasts unchanged, considering exchange rate and market situation. 2023 2024 Changes Previous Forecasts vs Previous Results Forecasts vs 2023 (as of May 14) Forecasts (as of Feb. 14) Sales 290.5 321.0 321.0 +30.4 - Operating profit 47.2 52.0 52.0 +4.7 - O.P.% 16.3%

  6. Slide 6: 2024 Forecasts by Segment

    2024 Forecasts by Segment (Billions of yen) Sales Operating profit 2023 2024 Changes 2023 2024 Changes Previous vs Previous Previous vs Previous Forecasts Forecasts Results Forecasts vs 2023 Results Forecasts vs 2023 (as of May 14) Forecasts (as of May 14) Forecasts (as of Feb. 14) (as of Feb. 14) A

  7. Slide 7: Operating Profit Analysis (vs 2024 Jan. – Mar.)

    Operating Profit Analysis (vs 2024 Jan. – Mar.)(Billions of yen) 2023 2024 Jan. – Mar. Jan. – Mar. Exchange Exchange Increase Increase Decrease Increase 10.45 Sales COGS impact for Gross Profit impact for Expenses R&D Expenses Other Expenses 10.00 -0.66 -0.06 +2.65 -1.25 -0.4 -0.69 Decrease Exchange

  8. Slide 8: Exchange Rate Trend / Forecasts / Impacts

    Exchange Rate Trend / Forecasts / Impacts 2023 2024 Previous Actual vs 2023 Annual Forecasts Forecasts (as of May 14) (Annual) (as of Feb. 14) 1Q USD 140.67 140 148.63 145 +4.33 EUR 152.11 155 161.33 160 +7.89 Exchange rate impact Exchange rate impact for 2024 Jan. – Mar. for 2024 Forecasts (vs 2023

  9. Slide 9: Capital Investment, Depreciation, R&D

    Capital Investment, Depreciation, R&D (Billions of yen) 2023 2024 2024 Previous vs Forecasts vs Actual Actual Forecasts Previous (as of May 14) 2023 Jan.-Mar. (as of Feb. 14) Forecasts Capex 9.1 23.0 23.0 +13.8 +0.0 3.0 Depreciation and amortization* 12.6 14.0 14.0 +1.3 +0.0 3.1 R&D expenses 20.4 22

  10. Slide 10: Shareholder Return

    Shareholder Return • Dividend payment = 30% of Consolidated net income attributable to HORIBA, Basic Policy Ltd.’s shareholders to be targeted • Execute special dividend and share buybacks timely and properly, considering investment opportunities and the cash flow situation. Dividends per share ⚫ 20

  11. Slide 11: Topics in 3 Fields

    Topics in 3 Fields © 2024 HORIBA, Ltd. All rights reserved. 11

  12. Slide 12: Contribute to productivity improvement in semiconductor production

    Materials & Semiconductor Contribute to productivity improvement in semiconductor production Release of Reticle / Mask Particle Detection System Total solution for CMP* slurries manufacturer Rapid inspection for particle contamination on reticles and Contribute to improving productivity Centrifugal

  13. Slide 13: Development in the Bio & Healthcare business

    Bio& Healthcare Development in the Bio & Healthcare business Investment for the growth in India Approach to global pharmaceutical market Background Background ➢ Increased demand for blood cell counts and clinical chemistry tests ➢ Speeding up of microbiological testing, aimed at improving ➢ Request

  14. Slide 14: Expansion of the hydrogen business in mobility field

    Energy & Environment Expansion of the hydrogen business in mobility field Accelerating development of solutions for fuel cell vehicle development using the STARS ①Fuel cell system Performance evaluation of fuel cells and 3 Evaluation facility for fuel cell power train peripherals, assuming actual us

  15. Slide 15: © 2024 HORIBA, Ltd. All rights reserved.

    © 2024 HORIBA, Ltd. All rights reserved.

HORIBA — Q1 2024 Earnings Presentation on 6ix